The Medicines Company (NASDAQ: MDCO) announced that the U.S. Food and Drug Administration (FDA) has approved the intravenous (IV) therapy CleviprexTM (clevidipine butyrate) injectable emulsion for the reduction of blood pressure when oral therapy is not feasible or not desirable.
Cleviprex, a novel IV antihypertensive, represents an advancement over currently available therapies, providing rapid and precise control of blood pressure Click here to read more.. »
March 28th 2008 Uncategorized
A recent paper published in the Journal of the American Society of Hypertension projected that the prevalence of premature coronary heart disease (CHD) in young adulthood will more than triple from five percent to 16 percent for currently obese adolescents when they reach 35 years of age. While lifestyle changes and appropriate medications are acknowledged as imperative, the author argues Click here to read more.. »
March 23rd 2008 Uncategorized
A new mouse model has provided some surprising insight into XLF, a molecule that helps to repair lethal DNA damage. The research, published by Cell Press in the September 5th issue of the journal Molecular Cell, suggests that although XLF shares many properties with well known DNA repair factors, certain cells of the immune system possess an unexpected compensatory mechanism that that can take Click here to read more.. »
March 18th 2008 Uncategorized
